Growth factors in the management of adult acute leukemia.
This review has explored the various ways that growth factors may be used in the management of adult acute leukemia. Growth factors have the potential to reduce the morbidity and mortality of both induction and postremission therapy by enhancing hematopoietic recovery or, when used as an adjunct to standard antimicrobial therapy, reducing the infectious complications of chemotherapy. In addition, they may have favorable effects on the biology of leukemia either by recruitment of leukemic progenitors into cycle, rendering them more sensitive to the cytotoxic effects of chemotherapy, or by inducing the terminal differentiation of the leukemic clone. Finally, disruption of aberrant growth factor networks, thought to play a role in the pathogenesis of leukemia, may be a therapeutic strategy now that soluble receptors and receptor antagonists to such growth factors as IL-1 are available. Whether growth factors used in such ways will have beneficial, or in fact adverse, effects on the treatment outcome for acute leukemia is not yet known. As such, the use of growth factors in the management of adults with acute leukemia is still experimental and needs to be studied in the context of clinical trials. Perhaps the ultimate benefit to be derived from the study of these growth factors will be a deeper understanding of the genetic perturbations that define the leukemic state. The development of molecular therapeutic techniques, such as gene transfer technology and the use of antisense oligonucleotides, has paralleled our increasing knowledge of cytokines. The hope is that as we come to understand leukemia at the molecular level, we will be able to develop the new therapeutic tools necessary to increase the numbers of patients cured.
Bernstein
S H
SH
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy; D002454:Cell Differentiation / Q000187:drug effects; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000493:pharmacokinetics; D004341:Drug Evaluation; D006133:Growth Substances / Q000627:therapeutic use*; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007938:Leukemia / Q000188:drug therapy / Q000628:therapy*; D008875:Middle Aged
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D006133:Growth Substances; D016298:Hematopoietic Cell Growth Factors; D007155:Immunologic Factors; D003561:Cytarabine